ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain
Aristeidis Lentzas(The Netherlands Cancer Institute), Olaf van Tellingen(The Netherlands Cancer Institute), Stefanie Zuidema(The Netherlands Cancer Institute), Mark C. de Gooijer(Manchester Academic Health Science Centre), Jos H. Beijnen(The Netherlands Cancer Institute), Amber Meurs(The Netherlands Cancer Institute), Nikkie Venekamp(The Netherlands Cancer Institute), Ceren H. Çitirikkaya(The Netherlands Cancer Institute)
Cited by 9
Related Papers
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
|PubMed|2002|507
Clinical Pharmacokinetics of Cyclophosphamide
|Clinical Pharmacokinetics|2005|451
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
|The Lancet Oncology|2018|419
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.
|Journal of Clinical Oncology|1993|313